Company Overview and News

 
China Approved Toshiba’s Chip Unit Sale: What It Means

2018-05-23 marketrealist
China has been delaying the approval of Toshiba’s (TOSYY) pending $18 billion sale of its memory unit to a consortium led by American private equity firm Bain Capital.

 
Micron Technology: Floating Gate Just Floats Away

2018-05-23 seekingalpha
"Floating Gate" and "Charge Trap" are the two different transistor technologies embedded in NAND memory. Stay with me! This is NOT a technical article.

 
Akamai, MUFG Tie-up to Bring Blockchain-Based Payment System

2018-05-23 zacks
Akamai Technologies (AKAM - Free Report) joined forces with Mitsubishi UFJ Financial Group Inc. (MUFG - Free Report) to deliver a new hyper-scale online payment network in Japan by first half of 2020. The payment network will be designed and deployed on Akamai Intelligent Platform and leverage blockchain architecture.

 
The Zacks Analyst Blog Highlights: Western Digital, Magna International, Nucor, Sony and Caterpillar

2018-05-22 zacks
Chicago, IL – May 22, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Western Digital Corporation (WDC - Free Report) , Magna International Inc. (MGA - Free Report) , Nucor Corporation (NUE - Free Report) , Sony Corporation (SNE - Free Report) and Caterpillar Inc.

 
Infineon to Build New Chip Plant in Austria Worth EUR 1.6B

2018-05-21 zacks
Infineon Technologies AG (IFNNY - Free Report) is set to build a new chip production house at Villach, Austria. The investment worth €1.6 billion is spread over a time period of six years.

 
Top Ranked Growth Stocks to Buy for May 21st

2018-05-21 zacks
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, May 21st:

 
Grab 5 Cheap Large-Cap Stocks on Eased US-China Trade Fear

2018-05-21 zacks
Trade worries between the United States and China, which cast a pall on Wall Street for months, have eased. This is especially true as the world’s largest economies dropped their tariff threats and set up a framework for addressing potential trade imbalances in the future. The Latest Development Beijing has agreed to substantially reduce America's massive trade deficit with China but did not commit any specific amount.

 
Canadian Solar, Anheuser-Busch InBev, Best Buy, Ralph Lauren and Urban Outfitters as Zacks Bull and Bear of the Day

2018-05-21 zacks
Chicago, IL – May 21, 2018 – Zacks Equity Research highlights Canadian Solar (CSIQ - Free Report) as the Bull of the Day and Anheuser-Busch InBev (BUD - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Best Buy (BBY - Free Report) , Ralph Lauren (RL - Free Report) and Urban Outfitters (URBN - Free Report) .

3
5 Low Price-to-Book Value Stocks to Buy Now

2018-05-21 zacks
In value analysis, though price to earnings (P/E) and price to sales (P/S) are most preferred by investors, the underrated price-to-book ratio (P/B ratio) is also an easy-to-use valuation tool for identifying low-priced stocks with exceptional returns. The ratio is used to compare a stock’s market value/price to its book value.

 
Zacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated National

2018-05-21 zacks
Chicago, IL – May 21, 2018 - Stocks in this week’s article Louisiana-Pacific Corp. (LPX - Free Report) , Amedisys Inc. (AMED - Free Report) , MGM Growth Properties LLC (MGP - Free Report) , Oshkosh Corporation (OSK - Free Report) and Federated National Holding Company (FNHC - Free Report) .

 
Zacks.com featured highlights include: Amtech, QuinStreet, Turtle Beach, Enova and Federated National

2018-05-21 zacks
Chicago, IL – May 21, 2018 - Stocks in this week’s article Amtech Systems, Inc. (ASYS - Free Report) , QuinStreet, Inc. (QNST - Free Report) , Turtle Beach Corp. (HEAR - Free Report) , Enova International Inc. (ENVA - Free Report) and Federated National Holding Company (FNHC - Free Report) .

 
Zacks.com featured highlights include: Ulta, Century Communities, NVIDIA, Cheniere and Progressive

2018-05-21 zacks
Chicago, IL – May 21, 2018 - Stocks in this week’s article Ulta Beauty, Inc. (ULTA - Free Report) , Century Communities, Inc. (CCS - Free Report) , NVIDIA Corporation (NVDA - Free Report) , Cheniere Energy Partners LP Holdings, LLC (CQH - Free Report) and The Progressive Corporation (PGR - Free Report) .

 
The Zacks Analyst Blog Highlights: Wells Fargo, Citigroup and JPMorgan

2018-05-21 zacks
Chicago, IL – May 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Wells Fargo (WFC - Free Report) , Citigroup (C - Free Report) and JPMorgan (JPM - Free Report) .

 
Zacks Industry Outlook Highlights: UnitedHealth, Anthem, Aetna, Cigna and Humana

2018-05-21 zacks
Chicago, IL – May 21, 2018 – Today, Zacks Equity Research discusses Health Insurance, including UnitedHealth Group Inc. (UNH - Free Report) , Anthem Inc. (ANTM - Free Report) , Aetna Inc. (AET - Free Report) , Cigna Corp. (CI - Free Report) and Humana Inc. (HUM - Free Report) .

 
Zacks Industry Outlook Highlights: Amazon.com, Berkshire Hathaway and JP Morgan

2018-05-21 zacks
Chicago, IL – May 21, 2018 – Today, Zacks Equity Research discusses Health Insurance, including Amazon.com, Inc. (AMZN - Free Report) , Berkshire Hathaway Inc. (BRK.B - Free Report) and JP Morgan (JPM - Free Report) .

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 958102105